



12/21/01

UTILITY**PATENT APPLICATION
TRANSMITTAL**(Only for new nonprovisional applications
under 37 CFR 1.53(b))

Attorney Docket No.: D/A0990

Total Pages:

First Named Inventor or Application Identifier

Michael B. Neary

Express Mail Label No.:

J1131 U.S. PTO
10/024416
12/21/01**APPLICATION ELEMENTS**See MPEP Chapter 600 concerning
utility patent application contents.ADDRESS TO: **Commissioner for Patents
Box Patent Application
Washington, DC 20231**

1. Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)

6. Microfiche Computer Program (Appendix)

2. Specification (incl. claims) (Total Pages: 13)

7. Nucleotide and/or Amino Acid Sequence Submission
(If applicable, all necessary)

3. Drawing(s) (35 USC 113) (Total Sheets: 2)

a. Computer Readable Copy
b. Paper Copy (Identical to computer copy)
c. Statement verifying identity of above copies

Informal Formal

Use Figure 2 for front page of Publication.

4. Oath or Declaration (Total Pages: 2)

ACCOMPANYING APPLICATION PARTS

a. Newly executed
(original or copy)

8. Assignment Papers (cover sheet & document(s))

b. Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]

9. 37 CFR 3.73(b) Statement Power of Attorney
(when there is an assignee)

i. **DELETION OF INVENTOR(S)**
Signed statement attached deleting
Inventor(s) named in the prior application,
see 37 CFR 1.63(d)(2) and 1.33(b).

10. English Translation Document (if applicable)

5. Incorporation By Reference
(usable if Box 4b is checked)

11. Information Disclosure
Statement (IDS)/PTO-1449 Copies of IDS
Citations

The entire disclosure of the prior application, from
which a copy of the oath or declaration is supplied
under Box 4b, is considered as being part of the
disclosure of the accompanying application and is
hereby incorporated by reference therein.

12. Preliminary Amendment

6. Microfiche Computer Program (Appendix)

13. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)

7. Nucleotide and/or Amino Acid Sequence Submission
(If applicable, all necessary)

14. Small Entity Statement(s) Statement filed in prior application,
Status still proper and desired

8. Paper Copy (Identical to computer copy)

15. Certified Copy of Priority Document(s)
(If foreign priority is claimed)

9. Statement verifying identity of above copies

16. Other:

17. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information:

Continuation Divisional Continuation-in-part (CIP) of prior application No: /

18. CORRESPONDENCE ADDRESS

<input type="checkbox"/> Same as prior application	<input checked="" type="checkbox"/> Correspondence address below				
NAME	Patent Documentation Center				
ADDRESS	Xerox Corporation, 100 Clinton Ave. S., Xerox Square 20th Floor				
CITY	Rochester	STATE	NY	ZIP CODE	14644
COUNTRY	U.S.A.	TELEPHONE	310-333-3662	FAX	585-423-5240 or 585-423-6059

Attorney Docket No. **D/A0990**

19. Cancel in this application original claims: _____ of the prior application before calculating the filing fee.
(At least one original independent claim is retained for this filing).

20. The filing fee is calculated below:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELED BY ABOVE-INDICATED AMENDMENT(S)				
(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
TOTAL CLAIMS (37 CFR 1.16(c))	14 - 20 =	0	X \$ 18	= \$0.00
INDEPENDENT CLAIMS (37 CFR 1.16(b))	3 - 3 =	0	X \$ 84	= \$0.00
MULTIPLE DEPENDENT CLAIMS (IF APPLICABLE) (37 CFR 1.16(d))		ANY -- 0	\$ 280	= \$0.00
BASIC FEE (37 CFR 1.16(a))				\$740.00
TOTAL				\$ 740.00

21. The Commissioner is hereby authorized to charge any filing or prosecution fees which may be required, under 37 CFR 1.16, 1.17, and 1.21 (but not 1.18), or to credit any overpayment, to Account No. 24-0025. An additional copy of this form is enclosed.

22. This is an authorization under 37 CFR 1.136(a)(3) to treat any concurrent or future reply, requiring a petition for extension of time, as incorporating a petition for the appropriate extension of time.

23. Amend the specification by inserting before the first line the sentence:
--This application is a continuation continuation-in-part divisional of Application(s) No(s). , filed .--

24. A CIP declaration is enclosed.

25. Power of Attorney

- The power of attorney appears in the original papers of the enclosed prior application.
- Enclosed is a copy of the declaration and power of attorney from the enclosed prior application.
- A new declaration with power of attorney is enclosed.

Attorney Docket No.: **D/A0990**

26. The following inventors named in the prior application are deleted per 37 CFR 1.53(b)(1), 1.63(d)(2) and 1.33 (b):

27. This application is adding one or more inventors under 37 CFR 1.48 to a previously executed application, with an enclosed: petition, fee, newly executed declaration from all inventors, and written consent of the assignee.

28. This application claims the priority benefit of one or more Provisional Application No(s). and the first sentence of this application has been or will be amended to so indicate.


29. Priority is claimed from
(reinsert all previous priority claims for the entire chain of any prior applications).

30. **This application is NOT to be published under 35 U.S.C. 122(b). The undersigned attorney or agent hereby certifies pursuant to 37 CFR §1.213, that the invention disclosed in this application has not been and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.**

31. The assignee of this application to be indicated on its publication is Xerox Corporation.

32. Other paper(s) enclosed:

Respectfully submitted,



Philip T. Virga

Signature per 37 CFR 1.33 & 34

Date: 12/20/2001

Registration No. 36,710

Telephone No. 310-333-3662